Clinical Trial Update: Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14 [Phase 2]

View source ↗

Summary

Phase 2 trial of lenvatinib in recurrent/metastatic adenoid cystic carcinoma of the salivary glands has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoid Cystic Carcinoma of the Salivary Glands

Drugs mentioned

• Lenvatinib (lenvatinib)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Adenoid Cystic Carcinomas of the Salivary Glands | Phase 2 | Status: COMPLETED